Han_2020_FEBS.Open.Bio_10_2375

Reference

Title : Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells - Han_2020_FEBS.Open.Bio_10_2375
Author(s) : Han B , Lee-Okada HC , Ishimine M , Orita H , Nishikawa K , Takagaki T , Kajino K , Yokomizo T , Hino O , Kobayashi T
Ref : FEBS Open Bio , 10 :2375 , 2020
Abstract :

Malignant mesothelioma (MM) is an aggressive malignant neoplasm which rapidly invades pleural tissues and has a poor prognosis. Here, we explore enhancement of the effect of irinotecan [camptothecin-11 (CPT-11)] by the p53-dependent induction of carboxylesterase 2 (CES2), a CPT-11-activating enzyme, in MM. The level of CES2 mRNA was greatly increased on treatment with nutlin-3a. A combination of CPT-11 and nutlin-3a inhibited the growth of MM cells more effectively than either drug alone. Knocking down CES2 in MM cells reduced the effect of the drug combination, and its forced expression in MESO4 cells enhanced the growth inhibitory activity of CPT-11 in the absence of nutlin-3a. Enhancement of the growth inhibitory activity of CPT-11 by nutlin-3a suggests a possible new combinatorial MM chemotherapy regimen.

PubMedSearch : Han_2020_FEBS.Open.Bio_10_2375
PubMedID: 32961616

Related information

Citations formats

Han B, Lee-Okada HC, Ishimine M, Orita H, Nishikawa K, Takagaki T, Kajino K, Yokomizo T, Hino O, Kobayashi T (2020)
Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells
FEBS Open Bio 10 :2375

Han B, Lee-Okada HC, Ishimine M, Orita H, Nishikawa K, Takagaki T, Kajino K, Yokomizo T, Hino O, Kobayashi T (2020)
FEBS Open Bio 10 :2375